白三烯受体调节剂治疗支气管扩张症的疗效观察
|
摘要
目的:探讨白三烯受体调节剂治疗支气管扩张症临床价值。方法:将81例确诊为支气管扩张症的患者,随机分为使用白三烯受体调节剂孟鲁司特片治疗组和不使用的空白组,比较两组治疗前及治疗后6个月急性加重的次数、平均痰量的变化、痰细菌学培养阳性结果次数、肺功能FVC(用力肺活量)的变化。结果:治疗前后痰量变化、急性加重次数变化具有统计学意义,治疗组痰量降低、急性加重次数减少(P<0.05)。各组FVC、痰细菌学培养阳性结果次数无明显差异(P>0.05)。结论:白三烯受体调节剂能减少支气管扩张症患者的痰量,降低患者急性加重发生率,有确切疗效。
Objective:Explore the leukotriene receptor modulators in the treatment of bronchiectasis disease clinical value.Methods:81cases of patients diagnosed with bronchiectasis,were randomly divided into the use of leukotriene receptor modulators meng Lu Si,treatment group and do not use the blank group,compared two groups before and after treatment The Times of acute exacerbation of six months,the change of the average amount of phlegm,sputum bacteriology training number of positive results,the change of lung function FVC.Results:Sputum volume changes before and after treatment, changes in the number of exacerbations statistically difference,drug group,the number of exacerbations reduce sputum volume(P<0.05).Between groups of FVC,sputum bacteriology training number of positive results no significant difference(P>0.05).Conclusions:Leukotriene receptor modulators can reduce the sputum volume of patients with bronchiectasis,reduce the incidence of patients with acute aggravating,have certain curative effect.
Objective:Explore the leukotriene receptor modulators in the treatment of bronchiectasis disease clinical value.Methods:81cases of patients diagnosed with bronchiectasis,were randomly divided into the use of leukotriene receptor modulators meng Lu Si,treatment group and do not use the blank group,compared two groups before and after treatment The Times of acute exacerbation of six months,the change of the average amount of phlegm,sputum bacteriology training number of positive results,the change of lung function FVC.Results:Sputum volume changes before and after treatment, changes in the number of exacerbations statistically difference,drug group,the number of exacerbations reduce sputum volume(P<0.05).Between groups of FVC,sputum bacteriology training number of positive results no significant difference(P>0.05).Conclusions:Leukotriene receptor modulators can reduce the sputum volume of patients with bronchiectasis,reduce the incidence of patients with acute aggravating,have certain curative effect.
引文
[1]朱元珏,陈文彬.呼吸病学[M].北京:人民卫生出版社,2002:892.
[2]梁结柱.长期小剂量阿奇霉素治疗支气管扩张症的疗效观察[J].中国现代医药杂志,2011,13(7):71-72.
[3]程涛.白三烯受体调节剂治疗支气管扩张症的疗效观察[J].中国当代医药,2012,10:89-90.
[4]顾晓花,沈策.长期小剂量阿奇霉素治疗支气管扩张症的疗效观察[J].中国感染与化疗杂志,2010,10(1):38-40.
[5]王曾礼.支气管扩张症的近代认识[J].中华肺部疾病杂志(电子版),2011,4(6):6-9.
[6]刘晓波.支气管扩张症48例诊治分析[J].中国误诊学杂志,2009,1.
[7]程远雄,黄东兰,覃月秋,等.支气管扩张症212例临床特点分析[J].南方医科大学学报,2011,31(9):1639-1640.
[8]王利刚.支气管肺泡保留灌洗联合阿奇霉素序贯治疗在支气管扩张合并感染中的应用价值研究[J].实用心脑肺血管病杂志,2010,18(12):1780-1781.
[9]杨卫星.阿奇霉素治疗下呼吸道感染的临床研究[J].亚太传统医药,2011,7:55.
[10]高蔚,翁婷.吸入激素对稳定期支气管扩张症患者痰中IL-6、IL-8、中性粒细胞表达的影响[J].临床肺科杂志,2008,13(9):1120-1121.
[11]丁会,王建国,孙晓艳,等.可逆性气流受限支气管扩张患者对支气管舒张药和糖皮质激素的反应性[J].吉林大学学报(医学版),2006,32(5):872-875.
[12]Wang W,Shen KL,Zeng JJ.Clinical studies of children with bronchiolitis obliterans[J].Zhonghua Er Ke Za Zhi,2008 Oct,46(10):732-738.
[13]Prescott WA Jr,Johnson CE.Antiinflammatory therapies for cystic fibrosis:past,present,and future[J].Pharmacotherapy,2005Apr,25(4):555-573.
[14]Corless JA,Warburton CJ.Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis[J].Cochrane Database Syst Rev,2000,4:CD002174.
[2]梁结柱.长期小剂量阿奇霉素治疗支气管扩张症的疗效观察[J].中国现代医药杂志,2011,13(7):71-72.
[3]程涛.白三烯受体调节剂治疗支气管扩张症的疗效观察[J].中国当代医药,2012,10:89-90.
[4]顾晓花,沈策.长期小剂量阿奇霉素治疗支气管扩张症的疗效观察[J].中国感染与化疗杂志,2010,10(1):38-40.
[5]王曾礼.支气管扩张症的近代认识[J].中华肺部疾病杂志(电子版),2011,4(6):6-9.
[6]刘晓波.支气管扩张症48例诊治分析[J].中国误诊学杂志,2009,1.
[7]程远雄,黄东兰,覃月秋,等.支气管扩张症212例临床特点分析[J].南方医科大学学报,2011,31(9):1639-1640.
[8]王利刚.支气管肺泡保留灌洗联合阿奇霉素序贯治疗在支气管扩张合并感染中的应用价值研究[J].实用心脑肺血管病杂志,2010,18(12):1780-1781.
[9]杨卫星.阿奇霉素治疗下呼吸道感染的临床研究[J].亚太传统医药,2011,7:55.
[10]高蔚,翁婷.吸入激素对稳定期支气管扩张症患者痰中IL-6、IL-8、中性粒细胞表达的影响[J].临床肺科杂志,2008,13(9):1120-1121.
[11]丁会,王建国,孙晓艳,等.可逆性气流受限支气管扩张患者对支气管舒张药和糖皮质激素的反应性[J].吉林大学学报(医学版),2006,32(5):872-875.
[12]Wang W,Shen KL,Zeng JJ.Clinical studies of children with bronchiolitis obliterans[J].Zhonghua Er Ke Za Zhi,2008 Oct,46(10):732-738.
[13]Prescott WA Jr,Johnson CE.Antiinflammatory therapies for cystic fibrosis:past,present,and future[J].Pharmacotherapy,2005Apr,25(4):555-573.
[14]Corless JA,Warburton CJ.Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis[J].Cochrane Database Syst Rev,2000,4:CD002174.